ZYDUS LIFESCIENCES LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Established: 1952-01-01

Employees: -

Market Cap: $13.6B

Website: http://cadilapharma.com

Clinical Trials

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Arm1
Drug: Arm 2

First Posted Date: 2024-05-03

Last Posted Date: 2024-12-20

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT06398808

Locations: 🇮🇳
ICON Hospital, Ahmedabad, Gujarat, India

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: ZYIL1 capsules 25 mg and 50 mg Placebo
Drug: ZYIL1 capsules 50 mg and 25 mg Placebo
Drug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
Drug: Matching placebo 25 mg and Matching placebo 50 mg

First Posted Date: 2023-08-08

Last Posted Date: 2024-12-19

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT05981040

Locations: 🇮🇳
KIMS-Kingsway Hospitals, Nagpur, Maharashtra, India
🇮🇳
CIMET's Inamdar Multispeciality Hospital, Pune, Maharashtra, India
🇮🇳
Sir Ganga Ram Hospital, New Delhi, India

and more 4 locations

A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

Phase 1

Recruiting

Conditions: Falciparum Malaria
Asymptomatic Condition
Uncomplicated Malaria

Interventions: Drug: ZY19489 + Ferroquine (FQ)
Drug: Placebo

First Posted Date: 2023-06-22

Last Posted Date: 2024-10-01

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 36

Registration Number: NCT05911828

Locations: 🇬🇦
Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon

A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Phase 4

Recruiting

Conditions: NAFLD
Type 2 Diabetes
Obesity
Dyslipidemias
Metabolic Syndrome

Interventions: Drug: Saroglitazar

First Posted Date: 2023-05-24

Last Posted Date: 2024-02-07

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 1500

Registration Number: NCT05872269

Locations: 🇮🇳
Gastroplus Digestive Disease Centre, Ahmedabad, India
🇮🇳
Medanta- TheMedicity, Gurgaon, India
🇮🇳
Mission GastroHospital, Ahmedabad, India

and more 16 locations

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Phase 4

Recruiting

Conditions: Chronic Kidney Diseases
Anemia of Chronic Kidney Disease

Interventions: Drug: Desidustat

First Posted Date: 2022-08-25

Last Posted Date: 2023-12-26

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 1004

Registration Number: NCT05515367

Locations: 🇮🇳
Indira Gandhi Institute of Medical Sciences, Sheikhpura, Bihar, India

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: Pertuzumab (Perjeta®)
Biological: Pertuzumab (ZRC-3277)

First Posted Date: 2022-03-17

Last Posted Date: 2024-07-18

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 268

Registration Number: NCT05283837

Locations: 🇮🇳
Unique Hospital-Multispeciality & Resesarch Institute, Sūrat, India

A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Placebo Capsule
Drug: ZY19489 Capsule

First Posted Date: 2022-01-25

Last Posted Date: 2022-07-11

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT05206201

Locations: 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

Phase 2

Completed

Conditions: Cryopyrin Associated Periodic Syndrome

Interventions: Drug: ZYIL1 capsule

First Posted Date: 2022-01-11

Last Posted Date: 2022-07-11

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 3

Registration Number: NCT05186051

Locations: 🇦🇺
Department of Clinical Immunology and Allergy, Adelaide, Australia

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ZYIL1 Capsule

First Posted Date: 2021-07-22

Last Posted Date: 2021-11-16

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 18

Registration Number: NCT04972188

Locations: 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ZYIL1 capsule

First Posted Date: 2021-01-29

Last Posted Date: 2021-06-18

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 30

Registration Number: NCT04731324

Locations: 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy